In this review:
Neoadjuvant talimogene laherparepvec + surgery for melanoma
Nivolumab +/- ipilimumab for stage IV melanoma
Adjuvant nivolumab vs ipilimumab in resected stage III/IV melanoma
5-year survival after nivolumab + ipilimumab in advanced melanoma
Cobimetinib + atezolizumab vs pembrolizumab in advanced melanoma
Nivolumab + ipilimumab for melanoma brain metastases
Nivolumab/dabrafenib/trametinib for BRAF-mutated metastatic melanoma
Talimogene laherparepvec + ipilimumab for advanced melanoma
Selumetinib +/- paclitaxel for metastatic uveal melanoma
Pembrolizumab + entinostat in metastatic uveal melanoma
Ipilimumab + nivolumab for stage III melanoma
Please login below to download this issue (PDF)